Company: TELO
Filing Date: 2025-07-17
Form Type: 8-K
Source: 0001641172-25-020042
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-07-17
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming
Chemotherapy and Rapamycin

New
data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering
stronger epigenetic effects than Paclitaxel or Rapamycin in aggressive PC3 tumor models.

On
July 17, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) reported new preclinical results evaluating the effects of its lead candidate,
Telomir-1, in a murine xenograft model using PC3 human prostate cancer cells. The data demonstrated that Telomir-1 reversed epigenetic
silencing by DNA methylation of the STAT1 gene, a tumor suppressor and immune response regulator, in a dose-dependent manner.

STAT1
is frequently silenced in advanced cancers via promoter hypermethylation, disrupting immune detection and apoptotic pathways. In this
study, Telomir-1 administered orally daily for 21 days resulted in full reversal of STAT1 hypermethylation in tumor tissue. No such reversal
was observed in the Paclitaxel (PTX) group, and only partial demethylation was observed with Rapamycin

In
addition to STAT1, Telomir-1 also reduced hypermethylation of TMS1 (also known as ASC or PYCARD), a pro-apoptotic tumor suppressor commonly
silenced in prostate cancer. While PTX and Rapamycin showed comparable or greater effects on TMS1 methylation, Telomir-1 is unique in
its ability to modulate both STAT1 and TMS1 - two genes that together regulate immune response and apoptosis.

Importantly,
TMS1 also plays a central role in inflammasome activation, which not only contributes to tumor cell death but also supports the immune
system’s ability to detect and clear abnormal cells. When TMS1 is hypermethylated, this immune signaling pathway is disrupted - reducing
caspase-1 activation and inflammatory cytokine release. This can impair immune surveillance and allow cancer cells to persist undetected.
By reducing TMS1 hypermethylation, Telomir-1 may help restore immune recognition and enhance the tumor’s sensitivity to both chemotherapy